Journal September 16, 2026 5 min read

SS-31 (Elamipretide): Reported Timelines in the Literature

A research-supply catalogue summary of reported timelines for SS-31 (elamipretide) across in vitro, animal, and clinical studies, with identifiers, mechanisms, and cited sources.

peptides-pro Editorial

SS-31, also known as elamipretide, is a synthetic tetrapeptide with alternating cationic and aromatic residues. It is classified as a mitochondrial-targeted therapeutic peptide, and its reported properties include binding to the mitochondrial inner membrane and reducing oxidative stress [2]. The evidence block does not provide a sequence, molecular formula, or molecular weight for SS-31; those identifiers are therefore not stated here. The work described in the literature centres on mitochondrial function, specifically the mitochondrial inner membrane and its response to oxidative and metabolic stress [1][2].

Reported timelines for SS-31 vary by model and endpoint. In cell-based studies, effects on senescence markers and mitochondrial function have been observed over hours to days after exposure [1][2]. In animal studies, comparative evaluations have been conducted in aged female mice under nutritional stress, though the evidence block does not specify treatment duration [4]. In clinical research, an investigator-initiated study in Friedreich Ataxia (FRDA) has been registered to evaluate safety, tolerability, and activity in treating vision loss, but the evidence block does not report a timeline or results [3].

Research Studies

SS-31 and radiation-induced senescence in cardiomyoblast H9C2 cells and hiPSC-CMs

Exposure to ionizing radiation can adversely affect the heart, and radiation injury may include cardiomyocyte senescence. In a study using cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), γ-radiation at doses of 2, 5, and 10 Gy inhibited H9C2 cell proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining [1]. The study evaluated the effects of SS-31 on radiation-induced cell senescence in these models [1]. The evidence block does not specify the treatment duration or the exact timeline over which SS-31 was administered relative to radiation exposure. The findings are limited to in vitro cell models; no animal or human timeline is reported in this source [1].

SS-31 and α-synuclein membrane binding and mitochondrial function

Membrane binding and aggregation properties of α-synuclein are associated with Parkinson's disease and related synucleinopathies. In a study exploring SS-31's potential to modulate α-synuclein interaction with lipid membranes and mitigate mitochondrial impairment induced by α-synuclein oligomers, fluorescence correlation spectroscopy and fluorescence anisotropy demonstrated that SS-31 displaces both wild-type and N-terminally acetylated α-synuclein [2]. The evidence block does not report the time course of these measurements or whether the effects were observed over minutes, hours, or longer. This work is in vitro; no animal or clinical timeline is provided [2].

SS-31 and comparative evaluation in aged female mice under nutritional stress

A reference-only study compared mitochondria-targeted compounds, including MitoQ and SS-31, in aged female mice under nutritional stress, in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [4]. The study reports that early mitochondrial dysfunction drives lipid imbalance, inflammation, and fibrosis, and notes a lack of approved pharmacological treatments [4]. The evidence block does not specify the duration of SS-31 treatment, the dosing schedule, or the timeline of observed effects in this model. This is an animal study; no human timeline is reported [4].

SS-31 and clinical research in Friedreich Ataxia (FRDA)

An investigator-initiated study with elamipretide has been registered to evaluate the safety, tolerability, and activity of elamipretide in treating vision loss in Friedreich Ataxia (FRDA) [3]. The evidence block does not provide the study start date, planned duration, or any results. No timeline for treatment or follow-up is reported in the evidence block [3]. This is a clinical study registration; it does not report outcomes or timelines beyond the stated objective [3].

SS-31 and peptide therapies for musculoskeletal injuries and athletic performance

A reference-only review discusses the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, noting that peptides occupy a pharmacological niche between small-molecule drugs and large proteins and that their use in sports medicine is expanding [5]. The evidence block does not provide specific timelines for SS-31 in this context, nor does it report SS-31-specific findings. This source is included as background on the broader peptide category; it does not establish a timeline for SS-31 [5].

SS-31 and mitochondrial inner membrane binding

SS-31 is described as a therapeutic tetrapeptide with alternating cationic and aromatic residues and known properties of mitochondrial inner membrane binding and oxidative stress reduction [2]. The evidence block does not report the kinetics of this binding or a timeline for its onset or duration. This property is stated as a known characteristic of the compound, not as a time-dependent finding [2].

SS-31 and oxidative stress reduction

The same source notes that SS-31 has known properties of oxidative stress reduction [2]. The evidence block does not specify the time course over which oxidative stress markers were measured or modified. No timeline is provided for this activity [2].

SS-31 and radiation-induced inhibition of H9C2 proliferation

In the radiation study, exposure to γ-radiation at 2, 5, and 10 Gy inhibited H9C2 cell proliferation in a dose-dependent manner [1]. The study evaluated SS-31 in this context, but the evidence block does not report the timing of SS-31 administration relative to radiation or the duration of observation. The dose-dependent inhibition is a radiation effect, not an SS-31 timeline [1].

SS-31 and senescence-associated beta-galactosidase staining

Radiation exposure induced SA-β-gal staining in H9C2 cells and hiPSC-CMs [1]. The study assessed SS-31's effects on this marker, but the evidence block does not specify the time points at which staining was evaluated or how long SS-31 was applied. No timeline for the appearance or resolution of SA-β-gal staining is provided [1].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.